Pharmacists can now refer to a new treatment algorithm for the metabolic management of Type 2 diabetes when caring for patients. This is one new addition to the Standards of Medical Care in Diabetes-2007 from the American Diabetes Association (ADA). The clinical practice guidelines have been updated to include new information about treatment and prevention that reflects the latest research.
As many as one in five Americans, or 55 million people, suffer with the abdominal discomfort associated with irritable bowel syndrome (IBS), according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Symptoms vary from patient to patient but typically include abdominal pain and discomfort with changes in bowel function-either predominantly diarrhea (IBS-d) or constipation (IBS-c). Some patients, however, experience a mixed form (IBS-m), with alternating diarrhea and constipation. Currently there exist few therapies for treating the condition; however, several entities in development look promising.
Two commonly prescribed antihypertensive medications have now been combined into one tablet. With an anticipated availability this September, valsartan (Diovan, Novartis) and amlodipine (Norvasc, Pfizer) will be sold as a combination product under the trade name Exforge (Novartis). The Food & Drug Administration approval is tentative, pending expiration of market exclusivity and patent protection for amlodipine in September.
According to the FDA Web site (www.fda.gov), 18 new molecular entities (NMEs) were approved in 2006, the lowest number to be given the nod by the agency since 2002 when only 17 drugs were approved.
The Centers for Medicare & Medicaid Services' proposal to share claims information data with researchers and other government agencies has met with widespread support as well as hope that the agency will take it even further. Pharmaceutical companies, some pharmacy organizations, and even Democratic Party leaders all welcomed the change, and many urged CMS to broaden the data sharing to include state Medicaid officials. The proposed rule change can be found in the Oct. 18, 2006, Federal Register
Pharmacists at one of the nation's largest military medical centers found that elderly patients are likelier to comply with drug regimens following a program of patient education, pharmacy counseling, and specially packaged drug blisterpacks. Jeannie Lee, Pharm.D., and Karen Grace, Pharm.D., clinical pharmacists at the Walter Reed Army Medical Center, led the research. "The Federal Study of Adherence to Medications in the Elderly" (FAME) was published in the Dec. 6 issue of the Journal of the American Medical Association.
At the ASHP Midyear Clinical Meeting in December, technology vendors from the largest system integrators to mom-and-pop software startups hawked their products and services. Bedside bar-coding, medication management tools, and smart pumps were among the dominant product categories displayed.
Last month, the House Ways and Means Committee held a hearing on patient safety and quality issues regarding end-stage renal disease (ESRD) treatment. In his opening remarks, outgoing committee chairman Rep. Bill Thomas (R, Calif.) acknowledged that Medicare payments for the treatment of ESRD increased by almost 50% between 1998 and 2003. In fact, epoetin alfa (Epogen, Amgen) has been identified as the single largest drug expenditure in Medicare Part B each year.
Sometimes in medication safety the simplest solution is the best.
With what may turn out to be a nationwide model, hospitals in San Diego have joined forces in an effort to reduce the number of adverse drug events (ADEs) associated with intravenous medication administration.
Final rules on hospital participation in Medicare and Medicaid may help pharmacists crack down on patients who try to provide their own drugs for hospital use. The practice is called "brown bagging," from the brown paper bags patients get from retail pharmacies.
Following months of anticipation and concern, in late December the Centers for Medicare & Medicaid Services issued a proposed rule governing Medicaid reimbursement that would cut more than $8 billion in Medicaid generic drug reimbursements over a five-year period. The ruling, which implements provisions of the Deficit Reduction Act of 2005 (DRA), drew sharp reactions from pharmacy industry organizations, which worried that it would have a profound and negative impact on patients and community pharmacy.
As Medicare Part D moves into its second year, the program has undergone modest yet important changes. Still, despite sometimes significant premium increases and lack of coverage in the donut hole, most seniors seem to be sticking with the prescription drug plans (PDPs) they picked last year.
A survey commissioned by pharmacist groups indicates once again that patients are often not adhering to directions for prescription medications.
The Centers for Medicare & Medicaid Services' proposal to share claims information data with researchers and other government agencies has met with widespread support as well as hope that the agency will take it even further. Pharmaceutical companies, some pharmacy organizations, and even Democratic Party leaders all welcomed the change, and many urged CMS to broaden the data sharing to include state Medicaid officials. The proposed rule change can be found in the Oct. 18, 2006, Federal Register
Multiple myeloma (MM) is not curable, according to the Multiple Myeloma Research Foundation (MMRF), but it is treatable. The MM panel of the National Comprehensive Cancer Network (NCCN) has added several drugs and drug combinations to the MM guidelines. Bortezomib (Velcade, Millennium Pharmaceuticals and Johnson & Johnson), lenalidomide (Revlimid, Celgene), and melphalan (Alkeran, GlaxoSmithKline) are all included in several combinations with cortico-steroids and other chemotherapy drugs. Lenalidomide is also recommended as single-agent treatment for salvage therapy.
The American Thoracic Society (ATS) recently issued a statement on the hepatotoxicity of antituberculosis medications. The statement, which appeared in the Oct. 15 issue of the American Journal of Respiratory and Critical Care Medicine, addresses the growing incidence of drug-induced liver injury (DILI) by tuberculosis medications.
Many agents are in development to fight resistance to Gleevec (imatinib, Novartis) in patients with chronic myeloid leukemia (CML). That was one of the issues highlighted at the recent meeting of the American Society of Hematology (ASH), held in Orlando, Fla. The meeting drew 20,000 attendees seeking news of improved treatments for blood cancer.
Last fall, the Infectious Diseases Society of America (IDSA) released updated guidelines for the diagnosis and treatment of Lyme disease. (See Drug Topics, Nov. 20, 2006, "Updated Lyme disease guide clarifies confusion".) Approximately one month later, Connecticut attorney general Richard Blumenthal issued a Civil Investigative Demand (CID) to look into possible antitrust violations by IDSA in connection with exclusionary conduct and monopolization in the development of its Lyme disease guidelines.
The Food & Drug Administration recently approved paliperidone (Invega, Janssen, L.P.), an atypical antipsychotic, for the treatment of schizophrenia, a disease that affects more than two million Americans. It is the first new treatment for schizophrenia to be approved since 2003.
House Democrats to push for Medicare drug negotiation
Maalox is a well-recognized brand name that healthcare professionals associate with nonprescription or OTC antacid drug products containing the active ingredients aluminum hydroxide, magnesium hydroxide, and simethicone. However, the Food & Drug Administration wants to alert healthcare professionals that Maalox Total Stomach Relief (an OTC upset stomach reliever/antidiarrheal drug product) contains the active ingredient bismuth subsalicylate.
CMS issued new rules governing Medicaid reimbursement on Dec. 22 that would cut more than $8 billion in Medicaid prescription generic drug reimbursements over a five-year period. Reimbursement for brand-name drugs would not be impacted, but CMS estimates it will reduce reimbursements for generics by $800 million in 2007 alone.
Pharmacists who want to opt out of the traditional career path should keep an eye on Thomas Menighan in Gaithersburg, Md. The former pharmacy owner and onetime American Pharmacists Association president created a new specialty. His current company, SynTegra, audits drug manufacturers, wholesalers, and other links in the pharmaceutical supply chain.
Picture this scenario: Family medicine residents complete a four-week rotation in a pharmacy, where they learn about the importance of collaborating with pharmacists to improve patient care. They also learn about over-the-counter medicines and how to write prescriptions.
South Carolina officials looking to reduce costs in the state Medicaid program have tapped pharmacists to help in the effort by improving drug selection and adherence. The South Carolina Department of Health & Human Services is offering a $1.98 million grant to the South Carolina College of Pharmacy (SCCP) to implement the program, which will focus on Medicaid patients diagnosed with mental health disorders, HIV/AIDS, or cancer.
With traumatic brain injury (TBI), the first question we often ask is, Will the patient recover? Beyond concerns about cognitive function and disability, little is generally known about the milestones and setbacks patients encounter while recovering from a TBI.
State and federal authorities are increasingly cracking down on pharmacies for fraud, waste, and abuse
